Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both GLP-1 and GIP, known as dual GLP-1/GIP ...

Novo Nordisk A/S’s appetite-blocking shot semaglutide, sold under the brand names Ozempic and Wegovy ... the US for diabetes ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

As the battle against obesity and diabetes heats up, two new superstars are entering the ring in Spain - Mounjaro (also known ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide ... year – once-weekly injections of tirzepatide at three dose levels – 5, 10, and 15 mg – achieved a 94% reduction ...

Mounjaro was approved by the Food and Drug Administration (FDA) in May and, while not rising to the level of game-changer, it’s a first-of-its-kind dual ... dose of 5 mg, 10 mg, or 15 mg, or ...

Viking Therapeutics reported promising early results for its experimental obesity pill, with increased weight loss at higher ...

Eli Lilly and Co.’s recent decision to drop development at phase II of PD-1 agonist peresolimab in rheumatoid arthritis (RA) because of an inadequate benefit-risk profile brought further attention to ...

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

staying closer to the starting dose of 0.25 milligrams, cutting down to as low as 0.1 milligrams or simply refraining from ...

Osteoarthritis of the knee is a common and often painful condition affecting millions worldwide, especially older adults. As ...